This company has been marked as potentially delisted and may not be actively trading. NYSE:BIOA (BIOA) (BIOA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipTrendsBuy This Stock About (BIOA) Stock (NYSE:BIOA) 30 days 90 days 365 days Advanced Chart Get (BIOA) alerts:Sign Up Key Stats Today's Range$4.40▼$5.0050-Day Range N/A52-Week Range$2.88▼$26.62Volume512,188 shsAverage Volume493,897 shsMarket Capitalization$139.99 millionP/E RatioN/ADividend YieldN/APrice Target$5.67Consensus RatingReduce Company OverviewBioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.Read More… Receive BIOA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (BIOA) and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOA Stock News HeadlinesInvitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CETMay 13 at 6:25 PM | finance.yahoo.comBioArctic: Exidavnemab phase 2a study expanded to include MSA patientsMay 8, 2025 | finanznachrichten.deTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. May 14, 2025 | Paradigm Press (Ad)Exidavnemab phase 2a study expanded to include MSA patientsMay 8, 2025 | finance.yahoo.comWith 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interestMay 6, 2025 | finance.yahoo.comBioAge Labs Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 6, 2025 | globenewswire.comThe European Commission refers lecanemab decision to Appeal CommitteeApril 1, 2025 | finance.yahoo.comJefferies Reaffirms Their Hold Rating on BioAge Labs, Inc. (BIOA)March 23, 2025 | markets.businessinsider.comSee More Headlines BIOA Stock Analysis - Frequently Asked Questions How were (BIOA)'s earnings last quarter? (BIOA) (NYSE:BIOA) issued its earnings results on Thursday, November, 7th. The biotechnology company reported ($6.70) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $6.08. When did (BIOA) IPO? (BIOA) (BIOA) raised $198 million in an initial public offering on Thursday, September 26th 2024. The company issued 11,000,000 shares at a price of $18.00 per share. When did the company's lock-up period expire? (BIOA)'s lock-up period expired on Tuesday, March 25th. (BIOA) had issued 11,000,000 shares in its IPO on September 26th. The total size of the offering was $198,000,000 based on an initial share price of $18.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are (BIOA)'s major shareholders? Top institutional shareholders of (BIOA) include Simplex Trading LLC, Charles Schwab Investment Management Inc. (0.25%), Bailard Inc. (0.07%) and Bank of New York Mellon Corp (0.06%). Insiders that own company stock include Vijay Satyanand Pande and Shane Barton. View institutional ownership trends. What other stocks do shareholders of (BIOA) own? Based on aggregate information from My MarketBeat watchlists, some other companies that (BIOA) investors own include ProQR Therapeutics (PRQR), Flexion Therapeutics (FLXN), Rite Aid (RAD), LadRx (CYTR), Intellipharmaceutics International (IPCIF), NVIDIA (NVDA) and AbbVie (ABBV). Company Calendar Last Earnings11/07/2024Today5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:BIOA CIK1534287 Webwww.bio-amber.com Phone+1-612-7474423FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$5.67 High Stock Price Target$7.00 Low Stock Price Target$5.00 Potential Upside/Downside+45.1%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares35,850,000Free FloatN/AMarket Cap$139.99 million OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NYSE:BIOA) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s third-term comments grabbed headlines, but the bigger story is what he’s planning next. A new report ...Porter & Company | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredA New Economic Shift – How You Can PrepareWhile everyone's focused on the Fed and interest rates... most investors are missing the real story. There'...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredDrop these 5 stocks now!You think the volatility is over? Think again … Because it’s just getting started. In fact, according...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (BIOA) Please log in to your account or sign up in order to add this asset to your watchlist. Share (BIOA) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.